us
asiapacif
econom
cooper
organ
defin
smallor
mediums
enterpris
sme
manufactur
compani
less
employe
nonmanufactur
compani
sale
less
similarli
uk
govern
small
busi
servic
agenc
depart
trade
industri
februari
defin
sme
busi
less
staff
japan
definit
sectordefin
tabl
broadli
compar
purpos
chapter
sme
defin
compani
fewer
peopl
staff
turnov
ignor
reader
recogn
fluid
natur
pharmaceut
industri
frequent
startup
merger
takeov
closur
indic
compani
describ
chapter
may
well
around
current
form
even
year
time
convers
compani
sme
year
ago
whose
activ
impact
drug
discoveri
greatli
expand
beyond
definit
impact
rel
compani
origin
sme
consequ
great
discuss
tradit
larg
multin
pharmaceut
compani
big
pharma
smallsiz
region
nation
pharma
compani
includ
chapter
except
insofar
deal
sme
impact
pipelin
purpos
chapter
drug
consid
includ
small
molecul
also
macromolecul
protein
antisens
agent
antibodi
vaccin
also
mention
pertin
chapter
definit
constitut
drug
discoveri
also
need
delin
put
chapter
context
purpos
chapter
author
taken
activ
phase
iia
proof
concept
clinic
trial
examin
role
sme
play
past
year
drug
discoveri
one
particular
impact
sme
drug
discoveri
far
patient
concern
proport
dug
patient
take
actual
origin
within
sme
consequ
survey
origin
new
chemic
entiti
nce
conduct
sme
industri
mostli
tend
fall
gener
banner
biotechnolog
biotech
sector
origin
group
scientist
entrepreneur
idea
technolog
intellectu
properti
ip
vision
consid
worthwhil
convert
busi
three
type
origin
discern
founder
frequent
origin
academ
research
institut
pharma
compani
divest
ip
research
center
scientist
pharma
compani
look
develop
technolog
outsid
parent
compani
public
fund
medic
research
past
year
concentr
clinic
genet
genom
molecular
biolog
biochemistri
field
rather
straightforward
medicin
chemistrydrug
discoveri
research
commerci
end
tend
regard
beyond
proper
use
public
fund
henc
discoveri
invent
might
lead
discoveri
new
drug
made
institut
conduct
academ
research
tend
licens
tradit
pharma
possibl
via
univers
technolog
transfer
offic
howev
mani
case
particularli
entrepreneuri
scientist
elect
commerci
ip
found
compani
new
sme
biotechnolog
sector
compani
born
two
exampl
use
illustr
univers
universityacadem
research
cluster
spawn
sme
engag
drug
research
biotechnolog
publish
may
offic
econom
research
california
trade
commerc
agenc
describ
california
home
publicli
fund
research
institut
surround
biotechnolog
compani
compani
employ
scientist
cowork
turnov
billion
time
california
also
receipt
billion
nation
institut
health
grant
imperi
colleg
scienc
technolog
medicin
ic
london
one
europ
largest
centr
crossdisciplinari
research
medic
school
alon
conglomer
former
chelsea
westminst
hospit
chare
cross
hospit
hammersmith
hospit
north
west
london
hospit
royal
brompton
hospit
st
mari
hospit
alli
exist
chemistri
biochemistri
molecular
biolog
research
depart
strong
crossdisciplinari
tie
led
recognit
ip
gener
may
manag
creation
spinout
compani
imperi
colleg
end
imperi
colleg
innov
set
facilit
spinout
well
licenc
ip
third
parti
tabl
list
imperi
colleg
spinout
compani
sme
list
imperi
colleg
innov
websit
engag
drug
research
role
smallor
mediums
enterpris
drug
discoveri
rj
reynold
tobacco
giant
spun
pharmaceut
busi
call
targacept
continu
work
therapeut
indic
ligand
bind
nicotin
acid
receptor
aventi
pharmaceut
spun
bone
research
group
asset
romainvil
site
pari
franc
becam
known
proskelia
merg
similar
compani
scotland
known
strachan
group
merg
entiti
known
prostrachan
group
recent
sanofiaventi
spun
antiinfect
group
parisbas
compani
known
novexel
novexel
inherit
advanc
portfolio
antiinfect
program
ip
receiv
million
financ
lifesci
investor
atla
ventur
sofinnova
abingworth
novo
galapago
joint
ventur
crucel
netherland
tibotec
belgium
found
fund
ip
parent
organ
fledgl
biotech
sme
whatev
origin
need
cash
signific
compar
sme
industri
sector
financ
may
come
privat
investor
busi
angel
ventur
capit
vc
compani
public
invest
typic
one
two
three
round
privat
fund
may
occur
compani
ip
asset
drug
prospect
revenu
make
attract
proposit
public
investor
public
invest
base
upon
proper
legal
financi
prospectu
usual
describ
flotat
initi
public
offer
ipo
final
invest
incom
drug
discoveri
activ
also
supplement
replac
sme
incom
stream
servic
product
busi
angel
typic
invest
hundr
thousand
dollar
new
busi
idea
within
short
timefram
success
small
compani
requir
substant
invest
sever
million
ten
million
dollar
exchang
equiti
compani
loan
combin
sever
round
vc
invest
known
seri
seri
b
etc
may
well
occur
sever
year
research
develop
r
necessari
translat
idea
asset
pass
round
may
fund
entir
exist
investor
new
investor
may
join
round
dilut
effect
exist
sharehold
time
usual
critic
get
best
term
condit
exist
new
investor
vc
compani
recogn
longev
invest
year
typic
time
requir
realiz
substanti
profit
invest
mani
vc
compani
special
invest
lifesci
compani
abingworth
advent
advent
intern
merlin
mvm
typic
uk
healthcar
compani
financi
case
vc
compani
associ
parent
organ
mvm
origin
uk
medic
research
council
desir
exploit
inspir
ip
valu
vcfund
sme
drug
discoveri
examin
report
commiss
pacif
bridg
life
scienc
weinberg
group
stoli
goodman
examin
impact
vc
invest
treatment
chronic
diseas
lead
caus
death
us
includ
cancer
heart
diseas
stroke
diabet
asthma
arthriti
author
assert
ventureback
medic
innov
develop
made
avail
patient
much
three
time
faster
bootstrap
approach
product
develop
report
claim
million
one
three
american
benefit
ventureback
medic
innov
develop
past
year
second
typic
vc
exit
sme
describ
section
sme
rais
initi
cash
requir
list
public
stock
exchang
usual
exchang
creat
riskier
ventur
impos
less
regul
report
list
compani
exampl
exchang
ofex
aim
uk
tecdax
germani
nasdaq
us
exampl
ukbas
contract
research
organ
biofocu
uk
rais
initi
fund
requir
place
ofex
cambridg
uk
base
structurebas
drug
discoveri
compani
sareum
list
aim
third
sourc
revenu
sme
engag
drug
discoveri
sell
licens
asset
technolog
servic
compani
within
drug
discoveri
sector
typic
offer
latestag
research
develop
product
big
pharma
consid
essenti
supplement
inhous
pipelin
sme
struggl
resourc
requir
cost
develop
typic
deal
run
hundr
million
dollar
includ
upfront
payment
mileston
payment
royalti
list
impact
inlicens
deal
pipelin
world
largest
pharmaceut
compani
januari
pfizer
discuss
section
altern
sme
seek
earn
revenu
offer
servic
big
pharma
sme
compani
technolog
area
resourc
compani
defici
big
pharma
offer
new
technolog
area
expertis
whatev
reason
larger
organ
elect
consid
better
outsourc
whole
part
trade
sme
tend
much
greater
albeit
sme
gener
less
cash
spend
deal
often
seek
partnership
describ
sharedrisk
wherebi
partner
contribut
resourc
project
object
share
reward
later
typic
sme
technolog
servic
compani
drug
discoveri
sector
includ
sell
technolog
perform
gene
sequenc
target
identif
valid
hitfind
lead
optim
compound
profil
good
laboratori
practic
good
manufactur
practic
preclin
clinic
studi
pharmaceut
profil
well
chemic
scaleup
typic
exampl
compani
discuss
section
ultim
revenu
gener
compani
also
second
altern
exit
vc
investor
trade
sale
compani
anoth
within
industri
trade
sale
may
big
pharma
biotechnolog
compani
case
incent
hunger
asset
technolog
workforc
case
cash
sme
acquir
substanti
reserv
investor
consid
would
better
place
elsewher
might
expect
deep
pocket
larg
pharma
financ
spectacular
deal
past
year
survey
typic
acquisit
main
establish
pharmaceut
player
shown
tabl
instruct
note
certain
compani
activ
acquir
sme
bolster
intern
drug
pipelin
technolog
base
howev
major
pharma
compani
conspicu
absenc
rise
biotechnolog
industri
world
caus
profound
shift
geograph
local
industri
away
tradit
pharma
center
often
locat
larg
industri
citi
cluster
around
major
academ
publicli
fund
research
foundat
west
coast
us
two
larg
thrive
cluster
distinguish
first
cluster
mani
regard
birthplac
biotechnolog
industri
locat
around
san
francisco
bay
area
california
geograph
concentr
term
biotech
bay
us
websit
biospac
cluster
around
univers
california
san
francisco
davi
berkeley
campus
compani
associ
research
institut
list
area
march
notabl
compani
began
life
sme
area
genentec
chiron
major
player
compet
big
pharma
worldwid
pharmaceut
market
notabl
sme
thrive
region
abgenix
chemocentryx
cv
therapeut
discoveri
partner
intern
exelixi
therav
known
advanc
medicin
gilead
second
us
westcoast
cluster
locat
south
california
around
san
diego
lo
angel
near
site
univers
california
san
diego
lo
angel
santa
barbara
irvin
campus
togeth
california
institut
technolog
salk
institut
scripp
research
institut
scientist
train
institut
launch
work
larg
number
local
compani
geograph
concentr
compani
research
institut
list
term
biotech
beach
american
websit
biospac
one
exampl
chemic
research
technolog
associ
professor
kc
nicola
scripp
research
institut
radiofrequ
tagmonitor
barcod
monitor
vial
use
combinatori
chemistri
commerci
sme
irori
subsequ
acquir
discoveri
partner
intern
san
diego
area
california
biotech
discuss
group
facilit
intercompani
exchang
inform
notabl
compani
san
diegolo
angel
area
amgen
grown
far
greater
sme
agouron
part
pfizer
idun
acquir
pfizer
cortex
idec
part
major
biotech
compani
biogen
idec
invitrogen
medigen
mycogen
sequenom
vical
east
coast
us
around
boston
huge
cluster
sme
biotechnolog
compani
mani
owe
origin
scientist
train
harvard
univers
massachusett
institut
technolog
mit
brandei
role
smallor
mediums
enterpris
drug
discoveri
role
smallor
mediums
enterpris
drug
discoveri
coloc
around
research
institut
univers
four
lead
hospit
involv
research
region
home
half
uk
top
london
stock
exchang
lse
quot
biotech
compani
ventur
capitalist
invest
billion
fund
europ
remark
cluster
grown
either
side
separ
sweden
denmark
smeinstitut
cluster
known
medicon
valley
websit
main
academ
center
area
includ
royal
danish
school
pharmaci
univers
copenhagen
copenhagen
denmark
lund
univers
sweden
group
povl
krogsgaardlarsen
royal
danish
school
pharmaci
long
conduct
research
treatment
neurodegen
disord
includ
research
muscarin
nicotin
acid
receptor
boston
consult
group
publish
report
medicon
valley
avail
medicon
valley
websit
report
show
particular
biotech
cluster
also
owe
much
exist
concentr
larg
mediums
pharma
region
pharmacia
much
biovitrum
astrazeneca
leo
lundbeck
novonordisk
spawn
larg
number
sme
compani
boston
consult
group
report
consid
medicon
valley
diabet
research
cluster
probabl
strongest
world
also
strong
emphasi
antiinflammatori
neurosci
drug
discoveri
notabl
drug
discoveri
associ
compani
sme
medicon
valley
pharma
acadia
pharmaceut
bioimag
zealand
pharmaceut
maxygen
pharmexa
topotarget
activ
biotech
notabl
european
cluster
locat
oxford
area
uk
around
munich
germani
leiden
netherland
around
pari
franc
rest
world
japan
one
import
sourc
new
drug
origin
major
compani
like
yamanouchi
fujisawa
takeda
parallel
drug
origin
much
smaller
research
group
kirin
breweri
nippon
flour
mill
teijin
etc
combin
past
success
reluct
industri
subject
merger
acquisit
activ
probabl
one
reason
emerg
biotech
cluster
seen
europ
us
yet
happen
merger
fujisawa
yamanouchi
announc
ambit
compani
like
takeda
may
allow
emerg
similar
concentr
sme
hitherto
compani
one
homegrown
japanes
sme
engag
drug
discoveri
sosei
locat
tokyo
founder
compani
shinichi
tamura
former
chief
execut
offic
genentech
japan
interest
one
japanes
pharmaceut
compani
tanab
deliber
creat
biotech
spinout
medicinova
base
san
diego
govern
assist
locat
drug
discoveri
sme
also
ignor
mani
govern
recogn
asset
strong
biotechnolog
busi
bring
countri
tax
advantag
often
given
compani
locat
certain
territori
countri
ambiti
singapor
creat
larg
scienc
park
end
academ
research
center
core
scienc
park
institut
molecular
cell
biolog
natur
product
research
cnpr
privat
becom
merlion
pharmaceut
genom
institut
singapor
form
john
hopkin
institut
offshoot
usbas
institut
name
major
compani
locat
singapor
glaxosmithklin
novarti
present
whilst
chiron
establish
bio
form
partnership
singapor
econom
develop
board
invest
edbi
bio
chemistrydriven
productori
compani
focu
cancer
object
identifi
develop
novel
smallmolecul
anticanc
drug
candid
leadingedg
research
well
joint
collabor
extern
partner
anoth
notabl
compani
locat
singapor
albani
molecular
contract
research
organ
headquart
albani
ny
us
cluster
hightech
sme
compani
engag
drug
discoveri
also
notabl
bangalor
region
india
around
shanghai
china
fate
smallor
mediums
enterpris
engag
drug
discoveri
compani
grown
size
challeng
major
tradit
pharma
compani
repres
aspir
ambit
compani
began
sme
biotech
compani
mani
thousand
startup
compani
hand
reach
exalt
posit
success
phenomen
one
major
caus
investor
seek
fund
sme
perform
drug
research
tradit
big
pharma
prior
except
vaccin
busi
almost
exclus
smallmoleculebas
rise
biolog
pharmaceut
therapi
base
upon
molecular
biolog
technolog
allow
sever
compani
amgen
genentech
biogen
idec
chiron
began
life
sme
becom
worldclass
player
right
despit
best
effort
big
pharma
compet
acquir
inde
except
genentech
majorityown
roch
remaind
maintain
independ
howev
salient
realiz
sme
becom
big
pharma
player
right
establish
research
develop
biolog
agent
antibodi
protein
rather
first
instanc
small
molecul
subsequ
success
gain
get
biolog
product
market
turn
smallmolecul
research
major
success
stori
sme
turn
major
competitor
tradit
big
pharma
shown
tabl
clearli
first
tier
market
capit
billion
amgen
genentech
actual
majorityown
roch
still
separ
quot
second
tier
market
capit
greater
billion
biogen
idec
gilead
chiron
end
chiron
agre
acquir
novarti
sepracor
tier
billion
millennium
vertex
cephalon
instruct
note
product
compani
reach
marketplac
thu
contribut
compani
achiev
fulli
integr
pharmaceut
compani
fipco
statu
genentec
genentec
found
san
francisco
acquir
roch
initi
invest
million
return
onehalf
genentech
outstand
common
stock
genentech
freestand
entiti
within
roch
impress
rang
mostli
biolog
product
actimmun
launch
treatment
infect
patient
chronic
granulomat
diseas
alteplas
recombin
tissu
plasminogen
activ
market
us
treatment
acut
myocardi
infarct
use
treatment
acut
pulmonari
embol
june
treatment
acut
ischem
stroke
within
h
symptom
onset
bevacizumab
intraven
administ
antivascular
endotheli
growth
factor
monoclon
antibodi
antiangiogenesi
therapi
treatment
colorect
cancer
dornas
alfa
dnase
develop
launch
treatment
cystic
fibrosi
efalizumab
human
monoclon
antibodi
onceweekli
subcutan
formul
treatment
moderatetosever
plaqu
psoriasi
kogen
recombin
human
factor
viii
prepar
use
treat
hemophiliac
omalizumab
antiig
human
monoclon
antibodi
treatment
asthma
recombin
somatotropin
first
launch
treatment
growth
hormon
defici
children
children
chronic
renal
insuffici
children
short
statur
associ
turner
syndrom
tenecteplas
inject
slowerclear
fibrinspecif
tissu
plasminogen
activ
treatment
myocardi
infarct
first
launch
us
june
eu
trastuzumab
human
version
monoclon
antibodi
market
treatment
metastat
breast
cancer
sinc
roferona
recombin
interferona
develop
use
treatment
variou
lymphoma
leukemia
neoplasm
treatment
chronic
hepat
b
c
viru
hbv
hcv
infect
ituximab
mousehuman
chimer
monoclon
antibodi
use
treatment
bcell
nonhodgkin
lymphoma
includ
relaps
refractori
lowgrad
follicular
lymphoma
role
smallor
mediums
enterpris
drug
discoveri
erlotinib
smallmolecul
oral
activ
epiderm
growth
factor
receptor
tyrosin
kinas
inhibitor
discov
relinquish
pfizer
merger
warnerlambert
treatment
nonsmallcel
lung
cancer
amgen
amgen
formerli
known
appli
molecular
genet
amgen
establish
headquart
thousand
oak
ca
amgen
origin
biotechnolog
compani
focus
develop
commerci
protein
antibodi
small
molecul
area
oncolog
inflamm
hematolog
nephrolog
neurolog
metabol
diseas
osteoporosi
amgen
done
share
acquisit
includ
purchas
kinetix
million
immunex
billion
tularik
billion
amger
extens
portfolio
product
anakinra
receptor
antagonist
develop
launch
extens
amgen
treatment
rheumatoid
arthriti
drug
origin
develop
collabor
research
univers
colorado
ancestim
recombin
human
stem
cell
factor
approv
mobil
stem
cell
treatment
cancer
darbopoetin
alfa
synthet
recombin
novel
erythropoiesisstimul
protein
treatment
anemia
associ
renal
diseas
epoetin
alfa
recombin
human
erythropoietin
market
us
sinc
orphan
drug
treatment
anemia
result
kidney
failur
first
erythropoietin
prepar
approv
treatment
anemia
prematur
infant
filgrastim
granulocyt
colonystimul
factor
product
initi
indic
reduct
incid
infect
manifest
febril
neutropenia
patient
undergo
myelosuppress
chemotherapi
interferon
consensu
interferon
indic
use
treatment
viral
infect
particularli
hepat
pegfilgrastim
sustaineddur
pegyl
form
recombin
granulocyt
colonystimul
factor
use
treatment
chemotherapyinduc
neutropenia
etanercept
solubl
tnf
receptor
tnfr
fusion
protein
treatment
adult
juvenil
ra
psoriat
arthriti
cinacalcet
calcimimet
treatment
primari
secondari
hyperparathyroid
market
product
biogen
idec
alefacept
tcellinhibit
antagonist
fusion
protein
launch
treatment
psoriasi
avonex
interferonb
use
sinc
treatment
relapsingremit
multipl
sclerosi
ibritumomab
tiuxetan
murin
monoclon
antibodi
conjug
either
radioimmunotherapi
relaps
refractori
lowgrad
follicular
transform
bcell
nonhodgkin
lymphoma
rituximab
mousehuman
chimer
monoclon
antibodi
use
treatment
bcell
nonhodgkin
lymphoma
includ
relaps
refractori
lowgrad
follicular
lymphoma
chiron
chiron
found
compani
clone
sever
hbv
antigen
sequenc
human
immunodefici
viru
hiv
genom
sequenc
hcv
genom
ip
form
basi
sever
chiron
product
also
gener
incom
licens
januari
novarti
own
chiron
outstand
common
stock
follow
allianc
establish
januari
februari
chiron
product
market
major
vaccin
nonvaccin
product
aldesleukin
recombin
compound
treatment
cancer
betaseron
recombin
interferon
b
treatment
relapsingremit
multipl
sclerosi
tobi
inhal
formul
antibiot
tobramycin
treatment
chronic
pseudomon
lung
infect
patient
cystic
fibrosi
pamidron
disodium
calcium
metabol
inhibitor
discov
henkel
germani
licens
novarti
amgen
treatment
moder
sever
paget
diseas
hypercalcemia
malign
multipl
myeloma
dexrazoxan
licens
british
technolog
group
use
chemotherapyinduc
cardiotox
sever
major
market
includ
us
pilocarpin
hydrochlorid
oral
formul
stimul
salivari
lacrim
secret
treatment
xerostomia
keratoconjunct
sicca
aris
number
condit
includ
autoimmun
diseas
radiotherapi
head
neck
chiron
announc
acquir
novarti
billion
cash
octob
gilead
contrast
biologyori
sme
success
sme
began
life
smallmolecul
drug
discoveri
hous
yet
becom
global
competitor
tradit
big
pharma
although
gilead
ligand
sepracor
vertex
millennium
probabl
closest
achiev
ambit
alreadi
grown
well
beyond
sme
definit
given
gilead
scienc
headquart
foster
citi
ca
found
employe
make
larg
fairli
consid
sme
gilead
sever
antiinfecti
product
market
emtricitabin
nucleosid
analog
licens
emori
univers
structur
relat
treatment
hiv
infect
cidofovir
specif
nucleotid
inhibitor
viral
replic
launch
inject
formul
oseltamivir
tamiflu
neuraminidas
inhibitor
treatment
prevent
influenza
viru
type
b
infect
tenofovir
disoproxil
fumar
oral
prodrug
intraven
administ
antivir
agent
tenofovir
use
treatment
prophylaxi
hiv
infect
ambisom
liposom
formul
amphotericin
b
jointli
develop
nexstar
lyphom
market
system
fungal
infect
us
cancer
acquir
immunodefici
syndrom
aid
patient
bloodborn
fungal
infect
adefovir
dipivoxil
analog
revers
transcriptas
inhibitor
adefovir
treatment
hbv
infect
ligand
pharmaceut
ligand
pharmaceut
san
diego
ca
found
develop
gene
transcript
technolog
particularli
intracellular
receptor
ir
technolog
signal
transduc
activ
transcript
stat
compani
appli
technolog
discov
develop
novel
smallmolecul
drug
treatment
cancer
osteoporosi
well
gynecolog
dermatolog
cardiovascular
inflammatori
diseas
ligand
compani
achiev
statu
launch
product
portfolio
includ
follow
us
food
drug
administrationapprov
drug
morphin
sulfat
extendedreleas
capsul
alitretinoin
bexaroten
denileukin
diftitox
vertex
pharmaceut
vertex
pharmaceut
found
initi
focus
structurebas
approach
drug
discoveri
headquart
cambridg
becam
publicli
own
biotechnolog
compani
juli
vertex
complet
agreement
sign
april
acquir
aurora
bioscienc
screen
technolog
compani
stockforstock
transact
fulli
dilut
equiti
valu
transact
million
februari
vertex
launch
one
product
fosamprenavir
prodrug
exist
hiv
proteas
inhibitor
amprenavir
treatment
hiv
infect
addit
vertex
first
origin
drug
invent
amprenavir
oral
nonpeptid
hiv
proteas
inhibitor
licens
develop
launch
extens
glaxo
wellcom
glaxosmithklin
treatment
hiv
infect
aid
millennium
pharmaceut
millennium
pharmaceut
found
biopharmaceut
compani
focus
discoveri
develop
small
molecul
biotherapeut
antibodi
protein
predict
medicin
product
februari
three
product
report
market
alemtuzumab
campath
lymphocytedeplet
human
monoclon
antibodi
treatment
chronic
lymphocyt
leukemia
eptifibatid
synthet
peptid
glycoprotein
iibiiia
antagonist
platelet
aggreg
inhibitor
deriv
rattlesnak
venom
intraven
treatment
acut
coronari
syndrom
bortezomib
ubiquitin
proteosom
inhibitor
treatment
multipl
myeloma
salutari
note
contrast
biolog
drug
hous
list
big
pharma
quicker
recogn
valu
smallmolecul
drug
research
hous
thu
prevent
mani
achiev
role
fipco
due
becom
acquisit
target
big
pharma
compani
includ
new
biotech
major
list
mani
case
sme
welcom
takeov
major
pharma
compani
way
realiz
valu
inher
ip
portfolio
illustr
acquisit
major
pharma
player
shown
tabl
mani
sme
would
fail
realiz
potenti
due
cash
exig
encourag
merg
acquir
sme
combin
two
compani
appear
synergist
way
realiz
invest
biotech
hunger
acquir
capabl
beyond
often
special
narrow
capabl
equal
encourag
vertic
merger
acquir
chemistri
capabl
logic
behind
fusion
sme
includ
lexicon
genet
coelacanth
us
etiolog
argenta
discoveri
uk
paradigm
amedi
uk
acquir
ip
asset
servic
compani
determin
becom
therapeut
player
also
engend
acquisit
evotecoai
purchas
evotec
neurosci
merg
two
therapeut
compani
togeth
cut
cost
whilst
maintain
synergi
also
import
caus
merger
ribotarget
british
biotechnolog
vernali
perform
threeway
merger
creat
singl
entiti
known
vernali
similarli
us
vi
technolog
vitex
surviv
compani
novemb
merger
pentos
pharmaceut
vi
technolog
vitex
merg
panaco
pharmaceut
earli
privat
placement
million
allow
financi
complianc
nasdaq
requir
deal
would
combin
vitex
antiinfect
capabl
therapeut
product
includ
panaco
pipelin
antivir
drug
antivir
drug
discoveri
platform
smallor
mediums
enterpris
fail
final
compani
merci
go
busi
axxima
ag
munich
germani
file
insolv
decemb
follow
acquisit
compani
gpc
biotech
ag
howev
bankruptci
total
closur
cambridg
uk
base
axi
genet
salutari
experi
industri
smallor
mediums
enterpris
drug
discoveri
hous
head
group
multitud
compani
neither
constrain
therapeut
area
prime
reason
exist
research
particular
technolog
axi
aderi
pharmaceut
aderi
pharmaceut
formerli
discoveri
therapeut
hopkinton
privat
own
pharmaceut
compani
found
creat
upon
ipresearch
program
whitbi
research
divis
ethyl
aderi
focus
r
smallmolecul
therapeut
use
treatment
central
nervou
system
cn
cardiovascular
renal
diseas
rotigotin
licens
schwarz
pharma
germani
develop
earli
stage
parkinson
diseas
selodenoson
select
adenosin
agonist
formul
intraven
administr
control
heart
rate
acut
attack
formul
oral
administr
chronic
manag
atrial
fibril
king
pharmaceut
bristol
tn
partner
binodenoson
project
adenosin
receptor
agonist
cardiac
pharmacolog
stressimag
araki
araki
saffron
walden
uk
found
januari
pharmaceut
compani
focus
treatment
inflammatori
diseas
oncolog
adjunct
therapi
advanc
drug
develop
chronic
obstruct
pulmonari
diseas
muscarin
antagonist
ad
develop
rheumatoid
arthriti
appar
singl
isom
racem
drug
market
unrel
indic
develop
pain
associ
cancer
emesi
associ
cancer
araki
acquir
japanes
biotech
sosei
juli
curagen
curagen
public
compani
locat
new
ct
form
genom
compani
singl
nucleotid
polymorph
technolog
recent
move
therapeut
axi
multitherapeut
axi
compani
recent
chang
strateg
direct
becom
preclin
clinic
develop
companya
move
advanc
pipelin
genomicsbas
therapeut
curagen
focus
human
fibroblast
growth
factor
treatment
oral
mucos
curagen
work
abgenix
fulli
human
monoclon
antibodi
specif
recogn
block
activ
form
pdgfd
plateletderiv
growth
factor
potenti
treatment
kidney
inflamm
potenti
treatment
metastat
melanoma
curagen
bayer
longstand
joint
interest
new
diabet
treatment
curagen
also
inlicens
topotarget
hdac
inhibitor
acquir
former
uk
sme
prolifix
potenti
treatment
cancer
also
investig
potenti
treatment
inflamm
curi
curi
public
compani
headquart
cambridg
establish
juli
merger
three
biotechnolog
sme
compani
creativ
biomolecul
ontogeni
reprogenesi
compani
special
develop
protein
small
molecul
modul
regulatori
pathway
control
repair
regener
cell
technolog
use
produc
potenti
therapeut
kidney
diseas
neurolog
disord
cancer
hair
growth
regul
cardiovascular
diseas
curi
special
therapeut
treatment
might
ensu
interfer
socal
hedgehog
pathway
product
includ
biolog
signal
protein
discov
scientist
curi
treatment
amelior
two
major
complic
chronic
kidney
diseas
smallmolecul
hedgehog
agonist
antagonist
exelixi
exelixi
san
francisco
ca
anoth
genomicsbas
model
system
pharmaceut
includ
fruitfli
nematod
worm
zebrafish
mous
drug
discoveri
compani
focus
mainli
develop
therapi
cancer
prolif
diseas
scientist
exelixi
done
larg
amount
work
receptor
tyrosin
kinas
enzym
import
angiogenesi
vascular
eg
metalloproteas
three
nuclear
receptor
liver
x
receptor
lxr
farnesoid
x
receptor
fxr
mineralocorticoid
receptor
mr
target
small
molecul
modul
modul
implic
variou
metabol
cardiovascular
disord
oncolog
program
focus
inhibit
raf
kinas
implic
cancer
therapeut
area
octob
exelixi
acquir
anoth
sme
xceptor
privat
corpor
form
ligand
pharmaceut
juli
research
identifi
therapeut
product
target
orphan
nuclear
receptor
use
technolog
exclus
licens
ligand
xceptor
focus
r
drug
treatment
cancer
cardiovascular
diseas
endocrin
disord
metabol
diseas
inflamm
medicinova
medicinova
found
septemb
tanab
seiyaku
japan
control
stake
locat
japan
san
diego
ca
product
project
includ
novel
oral
bioavail
compound
treatment
bronchial
asthma
action
includ
leukotrien
lt
receptor
antagon
inhibit
phosphodiesteras
iv
seri
benzimidazol
carbam
vasculartarget
agent
potenti
angiogenesi
inhibitor
treatment
cancer
myriad
myriad
genet
myriad
pharmaceut
two
part
salt
lake
citi
ut
locat
sme
two
myriad
compani
publicli
held
focu
gene
discoveri
analysi
develop
prophylact
therapeut
subsidiari
myriad
pharmaceut
predict
mutat
breast
cancer
gene
discoveri
prostat
cancer
gene
chromosom
gene
form
basi
polari
myriad
predict
test
assess
man
risk
develop
prostat
cancer
drug
discoveri
effort
target
cancer
rheumatoid
arthriti
acut
thrombosi
alzheim
diseas
hivaid
viral
diseas
oxagen
oxagen
abingdon
uk
form
april
spinout
genom
compani
wellcom
trust
centr
human
genet
mutat
biopharmaceut
compani
full
drug
pipelin
treatment
metabol
diseas
type
diabet
osteoporosi
endometriosi
inflammatori
diseas
rheumatoid
arthriti
inflammatori
bowel
diseas
psoriasi
asthma
oxagen
investig
antagonist
chemoattract
g
proteincoupl
receptor
gpcr
express
cell
potenti
treatment
asthma
allergi
larg
second
fundrais
complet
second
quarter
reox
spinout
compani
oxford
univers
uk
reox
drug
discoveri
compani
whose
technolog
base
bodi
biolog
respons
lack
oxygen
hypoxia
particular
mechan
activ
master
regul
hypoxiainduc
factor
activ
compani
build
research
academ
involv
develop
therapi
rang
diseas
could
benefici
regul
bodi
respons
oxygen
rigel
rigel
san
francisco
ca
pioneer
inhibit
syk
kinas
potenti
treatment
respiratori
diseas
rigel
enter
collabor
pfizer
pursu
clinic
develop
molecul
compound
rigel
syk
kinas
portfolio
develop
possibl
treatment
rheumatoid
arthriti
rigel
also
develop
smallmolecul
nonnucleosid
hcv
rna
polymeras
inhibitor
potenti
treatment
hcv
infect
merck
collabor
rigel
inhibit
ubiquitin
ligas
potenti
therapi
oncolog
also
develop
inhibitor
aurora
kinas
potenti
cancer
drug
sosei
sosei
found
base
tokyo
japan
biopharmaceut
compani
project
contracept
cancer
incontin
asthma
allergi
compani
main
strategi
use
drugreprofil
program
optim
find
new
indic
discontinu
drug
candid
mainli
japanes
compani
sosei
unusu
one
japanes
sme
biotech
compani
polici
inlicens
compound
alreadi
market
late
stage
develop
useu
compani
inlicens
compound
japanes
compani
via
drugreprofil
platform
sosei
acquir
uk
biotech
araki
juli
tularik
tularik
san
francisco
ca
found
biopharmaceut
compani
engag
r
drug
regul
gene
express
focus
cancer
immunolog
metabol
disord
amgen
acquir
tularik
tularik
stabl
amgen
batabulin
develop
batubulin
tubulin
polymer
inhibitor
potenti
treatment
variou
cancer
vernali
vernali
name
compani
creat
fusion
british
sme
biotechnolog
compani
vernali
alreadi
incorpor
vanguard
medica
ribotarget
british
biotechnolog
found
british
biotech
vernali
biotechnolog
compani
headquart
winnersh
uk
r
focu
migrain
thrombot
diseas
pain
parkinson
diseas
addit
earli
stage
research
oncolog
obes
inflamm
depress
one
vernali
predecessor
compani
ribotarget
licens
alfadolon
develop
monash
univers
australia
alfadolon
steroid
gaba
agonist
potenti
treatment
pain
especi
associ
cancer
vernali
done
deal
novarti
oncolog
target
project
anoth
agreement
biogen
idec
receiv
exclus
worldwid
right
vernali
adenosin
receptor
antagonist
program
agreement
biogen
idec
receiv
exclus
worldwid
right
develop
commerci
vernali
program
includ
compound
ver
novexel
novexel
pari
franc
sme
spinoff
aventi
merger
sanofisynthelabo
novexel
inherit
portfolio
antiinfect
drug
phase
clinic
trial
includ
oral
antibiot
bacteri
respiratori
infect
oral
streptogramin
consist
combin
type
streptogramin
type
streptogramin
potenti
treatment
communityacquir
pneumonia
respiratori
tract
infect
also
develop
treatment
sever
fungal
infect
oscient
therapeut
oscient
therapeut
cambridg
incorpor
genom
therapeut
antiinfect
compani
compani
origin
focus
discoveri
new
antibacteri
drug
longstand
research
agreement
scheringplough
discov
new
antibacteri
target
use
proprietari
genet
technolog
base
includ
databas
licens
sever
compani
pathogenom
oscient
chang
busi
focu
becom
commerci
organ
one
launch
productgemifloxacin
licens
lg
life
scienc
role
smallor
mediums
enterpris
drug
discoveri
cardiovascular
diseas
area
focu
major
pharma
biotech
compani
sme
arisen
academ
origin
cardiom
cardiom
formerli
nortran
pharmaceut
vancouv
canada
drug
discoveri
develop
compani
focus
treatment
prevent
cardiac
diseas
cardiom
focus
develop
within
two
area
cardiac
diseas
arrhythmia
congest
heart
failur
clinic
trial
rsd
arrhythmia
also
oxypurinol
congest
heart
failur
ion
channel
research
specialti
compani
cv
therapeut
cv
therapeut
palo
alto
ca
found
perform
r
cardiovascular
diseas
regadenoson
select
receptor
agonist
potenti
use
pharmacolog
stress
agent
myocardi
perfus
imag
studi
develop
cv
therapeut
japanes
compani
fujisawa
tecadenoson
select
receptor
agonist
potenti
reduct
rapid
heart
rate
atrial
arrhythmia
adentri
select
receptor
antagonist
potenti
treatment
heart
failur
licens
biogen
idec
cv
therapeut
licens
roch
also
develop
ranolazin
metabol
modul
partial
fatti
acid
oxid
inhibitor
potenti
treatment
angina
acut
coronari
syndrom
artesian
therapeut
artesian
therapeut
gaithersburg
md
privat
held
biopharmaceut
compani
focus
novel
diseasemodifi
diseaserevers
therapeut
treatment
cardiovascular
diseas
artesian
anoth
compani
develop
dualpharmacophor
molecul
contain
individu
pharmacophor
moieti
need
inhibit
two
target
link
togeth
flexibl
chemic
tether
singl
molecul
myogen
myogen
found
base
westminst
co
biopharmaceut
compani
engag
discoveri
develop
commerci
smallmolecul
therapeut
treatment
cardiovascular
disord
base
research
undertaken
univers
colorado
health
scienc
center
myogen
licens
aventi
sanofiaventi
develop
oral
formul
vasodil
phosphodiesteras
iii
inhibitor
enoximon
potenti
treatment
advanc
heart
failur
licens
abbott
oral
endothelin
antagonist
darusentan
potenti
treatment
uncontrol
hypertens
licens
abbott
research
group
formerli
basf
pharma
ambrisentan
endothelin
eta
antagonist
potenti
treatment
cardiovascular
diseas
term
target
discoveri
scientist
myogen
discov
nonfail
human
ventricular
myocardium
contain
larger
amount
fastcontract
alphamyosin
heavi
chain
alphamyhc
isoform
mrna
contrast
myocardi
failur
alphamyhc
mrna
markedli
downregul
slowcontract
isoform
betamyhc
upregul
thu
might
expect
agent
caus
revers
myhc
gene
switch
would
provid
therapeut
benefit
zealand
pharma
zealand
pharma
glostrup
denmark
found
privat
biopharmaceut
compani
focus
r
effort
develop
peptid
investig
gap
junction
modul
peptid
modif
chemistri
use
structureinduc
probe
technolog
compani
therapeut
focus
type
diabet
acut
heart
failur
arrhythmia
unmet
need
new
therapi
treat
cn
disord
one
especi
attract
scientist
clinician
investor
backer
consequ
larg
number
compani
creat
examin
mani
new
approach
huge
varieti
cn
indic
particularli
inform
exampl
impact
sme
cn
drug
discoveri
list
treatment
pain
bare
chang
two
centuri
use
morphin
longknown
deriv
diamorphin
wellknown
addict
respiratori
depress
side
effect
drug
caus
ionix
pharmaceut
cambridg
uk
base
ionix
pharmaceut
conduct
research
nonopi
treatment
pain
associ
use
proprietari
drug
target
involv
percept
signal
pain
peripher
nervou
system
treatment
might
use
pain
associ
chronic
debilit
diseas
osteoarthr
rheumatoid
arthriti
multipl
sclerosi
diabet
neuropathi
ionix
typic
sme
outsourc
much
research
partner
collabor
evotec
tripo
design
synthesi
druglik
chemic
compound
evalu
potenti
inhibitor
target
xenom
design
synthesi
screen
toxin
potenti
inhibitor
proprietari
ionix
drug
target
seri
smallmolecul
blocker
calcium
ion
channel
abl
enter
spinal
cord
preclin
pharmacokinet
investig
neuropath
pain
model
administr
result
almost
ident
concentr
role
smallor
mediums
enterpris
drug
discoveri
spinal
cord
plasma
revers
neuropath
hyperalgesia
observ
almost
h
ionix
acquir
vernali
uk
juli
chronogen
chronogen
montreal
canada
found
develop
therapeut
counter
effect
age
chronogen
focus
identif
character
longev
gene
clone
caenorhabd
elegan
mutant
exhibit
long
lifespan
phenotyp
gene
relev
human
diseas
select
basi
compani
drug
discoveri
program
chronogen
secur
exclus
worldwid
licens
protein
addit
seri
target
mcgill
univers
montreal
canada
target
investig
includ
regul
level
reactiv
oxygen
speci
regul
ubiquinon
synthesi
targacept
targacept
rtp
nc
spinout
tobacco
compani
rj
reynold
product
research
postop
pain
alzheim
diseas
targacept
research
novel
approach
treat
pain
includ
b
neuron
nicotin
acetylcholin
receptor
known
painreliev
effect
anim
neurogen
neurogen
incorpor
neuropharmaceut
compani
focus
r
smallmolecul
therapeut
treatment
neurolog
inflammatori
pain
metabol
disord
neurogen
develop
lead
seri
oral
antagonist
potenti
treatment
inflammatori
condit
includ
rheumatoid
arthriti
asthma
well
treatment
inflammatori
condit
neurogen
develop
select
gaba
modul
potenti
treatment
insomnia
decemb
compani
initi
phase
oral
dose
escal
trial
drug
neurogen
pfizer
also
develop
gabaa
agonist
potenti
treatment
insomnia
en
vivo
pharmaceut
treatment
alzheim
diseas
sever
unmet
medic
need
novel
approach
examin
varieti
compani
en
vivo
pharmaceut
cambridg
found
biopharmaceut
compani
dedic
discov
develop
drug
cn
disord
initi
focu
alzheim
parkinson
huntington
diseas
spinocerebellar
ataxia
use
technolog
licens
baylor
colleg
medicin
houston
tx
compani
insert
known
human
brain
diseas
gene
drosophila
fruitfli
examin
effect
candid
drug
whole
speci
en
vivo
pharmaceut
struck
deal
methylgen
quebec
canada
examin
use
latter
portfolio
histon
deacetylas
inhibitor
hitherto
almost
exclus
oncolog
therapi
alzheim
diseas
model
evotec
neurosci
evotec
neurosci
hamburg
germani
found
may
evotec
biosystem
professor
nitsch
evotec
neurosci
receiv
million
seri
fund
evotec
oai
five
ventur
capitalist
tvm
techno
ventur
manag
munich
germani
london
uk
mvm
london
uk
ventech
pari
franc
star
ventur
munich
germani
research
focu
alzheim
diseas
neurolog
disord
licens
roch
seri
subtypeselect
nmethyldaspart
antagonist
potenti
treatment
neurodegen
diseas
includ
stroke
evotec
neurosci
reacquir
entir
vc
investor
evotec
oai
march
dov
pharmaceut
new
drug
treat
depress
parkinson
diseas
special
dov
pharmaceut
biopharmaceut
compani
form
product
compani
attract
attent
merck
develop
licens
possibl
structur
shown
tripl
serotonin
norepinephrin
dopamin
reuptak
inhibitor
potenti
treatment
depress
merck
licens
exclus
worldwid
right
therapeut
indic
exclus
worldwid
right
treatment
depress
anxieti
addict
size
deal
struck
merck
impress
dov
would
receiv
million
upfront
licens
payment
million
achiev
certain
mileston
million
upon
achiev
certain
sale
threshold
merck
would
assum
respons
full
develop
manufactur
commerci
dov
investig
lead
seri
gabaa
modul
potenti
treatment
panic
disord
cn
product
dov
pharmaceut
ocinaplon
potenti
treatment
gener
anxieti
disord
neurocrin
bioscienc
neurocrin
bioscienc
san
diego
ca
found
focus
drug
discoveri
smallmolecul
therapeut
treat
diseas
central
nervou
immun
endocrin
system
neurocrin
develop
secondgener
corticotrophinreleas
factor
receptor
antagonist
potenti
treatment
cerebrovascular
ischemia
lead
stroke
one
seri
compound
result
neurocrin
work
excitatori
amino
acid
transport
modul
memori
pharmaceut
memori
pharmaceut
montval
nj
found
also
research
develop
potenti
drug
treat
alzheim
diseas
depress
schizophrenia
vascular
dementia
mild
cognit
impair
memori
impair
associ
age
compani
allianc
big
pharma
partner
includ
roch
look
compound
modul
ltype
calcium
channel
compound
modul
neuron
calcium
channel
regul
calcium
ion
flow
neuron
prevent
deleteri
consequ
excess
level
calcium
entri
one
benefit
modul
neuron
remain
respons
incom
signal
counteract
reduc
activ
normal
occur
age
march
least
one
compound
enter
clinic
trial
research
worker
memori
also
look
unusu
use
phosphodiesteras
type
iv
inhibitor
mild
cognit
impair
one
compound
mem
report
effect
hippocampusdepend
memori
task
wide
dose
rang
memori
also
project
examin
use
nicotin
receptor
agonist
includ
mem
schizophrenia
alzheim
diseas
newron
pharmaceut
newron
pharmaceut
spinout
form
closur
former
pharmacia
upjohn
research
center
milan
itali
newron
privat
biopharmaceut
compani
fund
privat
million
inject
two
round
financ
led
atla
ventur
apax
partner
fund
supplement
anoth
million
newron
focus
discoveri
develop
diagnost
therapeut
nervou
system
particularli
epilepsi
neurodegen
disord
pain
compani
run
preclin
research
earli
phase
clinic
develop
pursu
partner
continu
develop
lead
compound
safinamid
licenc
pharmacia
upjohn
sodiumchannel
blocker
calciumchannel
modul
glutam
releas
inhibitor
dopamin
metabol
modul
monoamin
oxidas
b
inhibitiondopamin
uptak
inhibitor
potenti
treatment
epilepsi
parkinson
diseas
restlessleg
syndrom
arexi
arexi
ab
molndal
sweden
drug
discoveri
develop
compani
focus
metabol
inflammatori
diseas
found
professor
holger
luthman
rikard
holmdahl
leif
andersson
dr
vidar
wendelhansen
common
interest
genet
genom
compani
biologydriven
proprietari
technolog
strong
focu
product
develop
use
forward
genet
highresolut
molecular
dissect
caus
diseas
mechan
typic
project
enhanc
action
bile
saltstimul
lipas
natur
occur
human
enzym
found
matur
pancrea
mother
milk
key
function
degrad
larg
spectrum
lipid
food
pharmaceut
use
recombin
human
bile
saltstimul
lipas
administ
oral
manufactur
cell
cultur
system
musculoskelet
diseas
compani
prostrakan
group
prostrakan
galashiel
scotland
merg
entiti
creat
strakan
group
former
aventi
spinout
sme
proskelia
pari
franc
creat
proskelia
former
bone
research
group
hoechst
marion
roussel
locat
former
romainvil
site
pari
franc
proskelia
form
research
arm
women
health
musculoskelet
compani
prostrakan
group
employ
peopl
make
combin
entiti
still
sme
definit
compani
essenti
european
focu
project
around
two
anabol
pathway
bone
morphogenet
protein
highbonemass
gene
mani
sme
compani
special
drug
discoveri
treat
cancer
reflect
larg
area
unmet
medic
need
avail
fund
research
treatment
major
econom
potenti
big
pharma
retain
major
interest
therapeut
area
consequ
spinout
origin
former
big
pharma
research
group
perceiv
eas
clinic
develop
persuad
sever
former
drug
discoveri
servic
sme
compani
chang
busi
model
wholli
partli
engag
proprietari
therapeut
research
field
notabl
arqul
array
bioscienc
thu
arqul
woburn
develop
topoisomeras
inhibitor
isol
lapacho
tree
caus
cell
cycl
arrest
potenti
use
chemotherapi
breast
ovarian
colorect
prostat
cancer
array
biopharma
boulder
co
investig
potenti
mek
inhibitor
potenti
treatment
cancer
sugen
one
origin
sme
engag
discov
inhibitor
kinas
anticanc
therapi
sugen
san
francisco
ca
acquir
pharmacia
part
pfizer
former
research
sugen
respons
number
clinic
drug
candid
develop
parent
organ
exampl
oral
activ
inhibitor
vascular
endotheli
growth
factor
receptor
kinas
pdgfrb
kit
tyrosin
kinas
signal
pathway
develop
potenti
anticanc
agent
base
intellectu
properti
gener
partli
professor
jame
staunton
group
biotica
focus
product
novel
biopharmaceut
target
alter
biosynthet
pathway
lead
polyketid
initi
focu
polyketid
antiinfecti
agent
appear
displac
potenti
use
oncolog
biotica
polyketid
mammalian
target
rapamycin
mtor
inhibitor
kda
heat
shock
protein
inhibitor
novel
angiogenesi
inhibitor
biotica
technolog
platform
compris
method
genet
engin
polyketid
synthas
associ
postpolyketid
synthas
gene
cytokinet
cytokinet
establish
headquart
san
francisco
ca
biopharmaceut
compani
focus
r
commerci
novel
smallmolecul
drug
june
cytokinet
glaxosmithklin
enter
strateg
collabor
r
commerci
novel
smallmolecul
therapeut
target
mitot
kinesin
applic
treatment
cancer
diseas
cytokinet
glaxosmithklin
develop
mitot
kinesin
spindl
protein
inhibitor
potenti
treatment
variou
cancer
cytokinet
glaxosmithklin
develop
lead
seri
mitot
kinesin
spindl
protein
inhibitor
potenti
treatment
cancer
eirx
therapeut
anoth
compani
interest
kinas
potenti
treatment
cancer
genomicsbas
eirx
therapeut
cork
ireland
public
lseaim
compani
found
research
apoptot
mechan
cell
death
compani
identifi
apoptosisassoci
gene
target
use
proprietari
genom
model
system
alibi
silenc
rna
technolog
gpc
biotech
gpc
biotech
munich
germani
form
headquart
munich
germani
publicli
own
genom
proteomicsbas
compani
focus
discoveri
develop
commerci
anticanc
drug
antiinfect
research
abandon
compani
chang
name
gpc
biotech
march
follow
acquisit
usbas
sme
mitotix
gpc
biotech
acquir
asset
insolv
axxima
specialist
kinas
compani
march
kudo
kudo
cambridg
uk
privat
oncolog
compani
access
ip
professor
stephen
jackson
laboratori
univers
cambridg
uk
kudo
cancer
research
uk
develop
lomeguatrib
alkyltransferas
inhibitor
discov
paterson
institut
cancer
research
triniti
colleg
dublin
kudo
also
interest
inlicens
origin
de
montfort
univers
candid
drug
hypoxiaselect
cytotox
prodrug
potenti
oncolog
treatment
kudo
acquir
astrazeneca
end
methylgen
methylgen
form
quebec
canada
sme
engag
r
commerci
enzym
inhibitor
treatment
cancer
also
infecti
diseas
compani
form
role
smallor
mediums
enterpris
drug
discoveri
joint
ventur
hybridon
three
canadian
vc
partner
methylgen
ip
field
histon
deacetylas
inhibitor
dna
methyltransferas
inhibitor
methylgen
mgi
pharma
develop
secondgener
antisens
oligonucleotid
inhibit
express
dna
gene
potenti
treatment
cancer
bio
bio
see
section
anoth
cancer
compani
partli
fund
chiron
locat
singapor
spectrum
pharmaceut
spectrum
pharmaceut
formerli
neotherapeut
irvin
ca
list
compani
specialist
oncolog
inlicens
compani
cn
research
axi
curtail
spectrum
develop
former
eortc
european
organis
research
treatment
cancer
compound
apaziquon
first
synthes
potenti
treatment
bladder
cancer
radiat
sensit
solid
tumor
licens
bm
elsamitrucin
topoisomeras
ii
inhibitor
antidna
gyras
activ
actinomycet
ferment
product
potenti
treatment
nonhodgkin
lymphoma
spectrum
also
licens
seri
endothelin
b
agonist
chicago
lab
turn
obtain
univers
illinoi
topotarget
topotarget
copenhagen
denmark
found
specialist
oncolog
compani
focus
discoveri
develop
smallmolecul
drug
cancer
lead
compound
topoisomeras
ii
inhibitor
nich
indic
extravas
topotarget
acquir
abingdon
uk
oncolog
sme
prolifix
along
oncolog
product
action
histon
deacetylas
respiratori
diseas
inflamm
compani
new
smallmolecul
drug
treat
rheumatoid
arthriti
inflammatori
bowel
diseas
respiratori
diseas
rare
even
big
pharma
stabl
abandon
interest
domain
bayer
withdraw
respiratori
therapeut
area
exampl
initi
format
two
spinoff
compani
former
bayer
scientist
etiolog
uk
see
aerov
berkeley
ca
aerov
began
two
exbay
product
recombin
human
antagonist
receptor
sever
asthma
recombin
human
proteas
inhibitor
inhibit
sodium
ion
channel
may
therapi
cystic
fibrosi
patient
therav
therav
formerli
advanc
medicin
san
francisco
us
although
entir
special
respiratori
therapeut
area
perform
major
research
longact
bagonist
multim
pharmacophor
approach
new
respiratori
drug
struck
major
deal
codevelop
drug
domain
glaxosmithklin
agreement
march
therav
licens
novel
dualact
b
antagonistmuscarin
agonist
molecul
glaxosmithklin
argenta
discoveri
argenta
discoveri
harlow
uk
origin
spinout
ic
london
uk
former
group
dagenham
merger
etiolog
argenta
declar
intern
discover
new
drug
chronic
obstruct
pulmonari
diseas
virtu
etiolog
prior
acquisit
preclin
research
group
bayer
uk
avidex
avidex
oxford
uk
privat
drug
discoveri
compani
form
spinout
oxford
univers
exploit
technolog
aris
institut
molecular
medicin
compani
focus
develop
tcell
receptorbas
therapeut
treatment
cancer
autoimmun
diseas
avidex
licens
activ
biotech
exclus
develop
market
right
antagonist
potenti
treatment
autoimmun
diseas
includ
rheumatoid
arthriti
topigen
topigen
quebec
canada
found
biotechnolog
compani
engag
r
antisens
drug
asthma
allerg
rhiniti
respiratori
diseas
chronic
obstruct
pulmonari
diseas
cotherix
cotherix
formerli
exhal
therapeut
base
san
francisco
ca
privat
held
biopharmaceut
compani
form
februari
commerci
research
perform
columbia
univers
new
york
cotherix
exclus
us
develop
market
right
iloprost
synthet
prostacyclin
analog
treatment
primari
pulmonari
hypertens
first
develop
schere
compani
chang
name
exhal
focus
develop
therapi
treat
inflammatori
lung
diseas
smallor
mediums
enterpris
special
drug
discoveri
specif
target
class
disciplin
arena
pharmaceut
arena
pharmaceut
san
diego
ca
found
special
discoveri
develop
therapeut
particularli
act
orphan
gpcr
use
constitut
activ
receptor
technolog
melanophor
technolog
arena
develop
seri
oral
activ
smallmolecul
agonist
potenti
treatment
obes
diabet
invers
agonist
potenti
treatment
insomnia
arena
agonist
gpcr
potenti
treatment
inflammatori
diseas
includ
asthma
pulmonari
fibrosi
inflammatori
bowel
diseas
arena
pharmaceut
orthomcneil
investig
oral
activ
agonist
gpcr
potenti
treatment
type
diabet
pharma
pharma
horshoom
denmark
investig
seri
antagonist
receptor
chemoattract
receptorhomolog
molecul
express
thelper
type
cell
potenti
treatment
allergi
asthma
inflamm
also
identifi
ureidobenzamid
compound
melaninconcentr
hormon
receptor
type
antagonist
compani
also
interest
ghrelin
receptor
agonist
potenti
treatment
obes
adenosin
therapeut
adenosin
therapeut
charlottesvil
wv
biotechnolog
compani
focus
r
agonist
antagonist
adenosin
receptor
subtyp
medic
imag
potenti
treatment
inflamm
chronic
obstruct
pulmonari
diseas
diabet
asthma
parkinson
diseas
pain
angiogenesi
epilepsi
juvantia
pharma
juvantia
pharma
turku
finland
found
compani
discov
develop
smallmolecul
pharmaceut
activ
transmembran
signal
via
gpcr
program
includ
develop
treatment
neurodegen
diseas
mental
disord
vascular
wall
disord
project
includ
adrenoceptor
antagonist
fipamezol
potenti
treatment
parkinson
diseas
g
proteincoupl
adrenoceptor
antagonist
potenti
treatment
cardiovascular
ailment
n
nh
f
kinas
popular
target
class
drug
discoveri
particularli
oncolog
field
also
inflamm
consequ
mani
compani
alreadi
discuss
oncolog
specialti
compani
could
equal
place
section
sugen
sugen
san
francisco
ca
major
independ
sme
player
kinas
acquir
pharmacia
part
pfizer
activx
activx
san
diego
ca
compani
special
kinas
proteas
drug
discoveri
activx
bioscienc
origin
licens
technolog
scripp
research
institut
form
basi
proteom
platform
activx
subsidiari
japanes
compani
kyorin
axxima
axxima
munich
germani
special
research
kinas
subsum
gpc
biotech
ag
specialist
anticanc
compani
march
cellular
genom
cellular
genom
branford
ct
compani
special
field
function
genom
target
valid
drug
discoveri
among
asset
cgi
exclus
licens
proprietari
gene
protein
analysi
technolog
yale
princeton
univers
cellular
genom
gener
lead
seri
kinas
inhibitor
demonstr
concurr
inhibit
critic
set
angiogenesi
cancerrel
kinas
includ
vegfr
ckit
piram
piram
slough
uk
form
spinout
sever
academ
cancer
research
organ
ludwig
institut
cancer
research
cancer
research
uk
institut
cancer
research
uk
piram
drug
discoveri
research
signal
transduct
inhibitor
princip
superfamili
lipid
kinas
exemplifi
phosphatidylinositol
upstat
biotechnolog
upstat
biotechnolog
subsidiari
serolog
atlanta
ga
offer
broadspectrum
kinasescreen
servic
industri
show
kinas
select
kinas
project
often
requir
due
presenc
approxim
kinas
enzym
superfamili
zinc
fingerbind
domain
compani
sangamo
bioscienc
sangamo
richmond
ca
special
find
drug
act
zinc
fingerbind
domain
exampl
drug
upregul
vegf
vegf
receptor
treat
coronari
arteri
diseas
peripher
arteri
diseas
sangamo
also
enter
joint
collabor
edward
develop
zfptherapeut
downregul
phospholamban
gene
target
role
calcium
flux
heart
muscl
believ
directli
involv
congest
heart
failur
antibodi
protein
sirna
therapi
gene
therapi
compani
given
success
sme
compani
special
new
biolog
entiti
becom
power
compani
pharmaceut
industri
instruct
see
new
compani
field
abgenix
abgenix
fremont
ca
incorpor
june
wholli
own
subsidiari
cell
genesi
subsequ
becam
independ
valuat
februari
million
rank
well
biogen
idec
better
mani
smallmolecul
compani
abgenix
use
xenomous
technolog
enabl
rapid
gener
highaffin
fulli
human
antibodi
product
candid
medicin
abgenix
allianc
astrazeneca
cancer
target
sosei
amgen
panitumumab
human
monoclon
antibodi
epiderm
growth
factor
receptor
use
monotherapi
combin
agent
treatment
solid
tumor
curagen
fulli
human
monoclon
antibodi
specif
recogn
block
activ
form
plateletderiv
growth
factor
potenti
treatment
immunoglobulin
nephropathi
allig
bioscienc
allig
bioscienc
lund
sweden
found
develop
new
optim
exist
therapeut
diagnost
product
allig
pipelin
potenti
treatment
rheumatoid
arthriti
acut
myocardi
infarct
acut
inflamm
allig
proprietari
fragmentinduc
divers
find
technolog
conduct
protein
optim
technolog
involv
fragment
dna
encod
particular
protein
interest
recombin
test
express
protein
improv
origin
domanti
domanti
cambridg
us
cambridg
uk
privat
compani
found
use
ip
sir
greg
winter
dr
ian
tomlinson
medic
research
council
laboratori
molecular
biolog
drug
discoveri
compani
develop
antibodi
molecul
human
domain
antibodi
therapeut
molecul
small
highli
stabl
like
human
antibodi
design
specif
high
affin
biolog
target
interest
domanti
dozen
proprietari
domain
antibodi
therapeut
program
primarili
field
inflamm
oncolog
includ
human
domain
antibodi
neutral
cytokin
medarex
medarex
princeton
nj
public
us
compani
found
biopharmaceut
compani
focus
discoveri
develop
fulli
human
antibodybas
therapeut
treat
lifethreaten
debilit
diseas
includ
cancer
inflamm
autoimmun
infecti
diseas
use
ultimab
human
antibodi
develop
system
compani
creat
human
antibodi
use
transgen
mice
medarex
collabor
bm
investig
fulli
human
antibodi
clinic
trial
metastat
melanoma
amgen
morphosi
morphosi
base
martinsriedplanreg
germani
found
biotechnolog
compani
focus
develop
antibodybas
product
treat
infecti
diseas
cancer
inflamm
compani
proprietari
technolog
includ
human
combinatori
antibodi
librari
project
declar
morphosi
websit
includ
mor
mor
fulli
human
hucal
gold
antibodi
direct
inflamm
target
intercellular
adhes
also
known
mor
fab
fragment
develop
treat
skin
burn
deep
dermal
burn
mor
immunoglobulin
g
antibodi
intend
psoriasi
xoma
xoma
berkeley
ca
biopharmaceut
compani
develop
manufactur
genet
engin
protein
peptid
monoclon
antibodi
pharmaceut
target
includ
cancer
immunolog
disord
inflammatori
disord
infecti
diseas
primari
drug
develop
platform
bactericid
permeabilityincreas
protein
human
host
defenc
protein
multipl
antiinfect
properti
partner
genentech
serono
xoma
market
new
biolog
entiti
efalizumab
therapi
continu
control
chronic
moderatetosever
plaqu
psoriasi
cambridg
antibodi
technolog
cambridg
antibodi
technolog
cat
cambridg
uk
began
life
subsidiari
peptid
technolog
peptech
januari
cat
spunoff
freestand
entiti
complet
ipo
cat
develop
novel
human
monoclon
antibodybas
therapeut
product
base
proprietari
antibodi
phage
display
technolog
platform
well
licens
technolog
capabl
other
develop
product
cat
first
product
adalimumab
isol
optim
collabor
abbott
approv
market
treatment
rheumatoid
arthriti
countri
cat
also
broad
collabor
genzym
develop
commerci
antibodi
direct
transform
growth
famili
protein
associ
fibrosi
scar
may
cat
offer
acquir
astrazeneca
isi
pharmaceut
isi
pharmaceut
carlsbad
ca
found
order
explor
potenti
antisens
technolog
compani
antisens
drug
design
treat
bone
cardiovascular
infecti
metabol
inflammatori
diseas
well
cancer
research
area
isi
strong
focu
ribonucleas
h
isi
research
worker
publish
small
interf
rna
motif
consist
entir
omethyl
fluoro
nucleotid
display
enhanc
plasma
stabil
increas
vitro
potenc
oxford
biomedica
oxford
biomedica
oxford
uk
establish
spinout
oxford
univers
biopharmaceut
compani
involv
develop
gene
therapi
treatment
focu
oncolog
neurotherapi
oxford
biomedica
develop
lentiviru
lack
mani
accessori
gene
claim
caus
fewer
unwant
side
effect
use
gene
therapi
oxford
biomedica
investig
lentiviru
vector
potenti
use
gene
therapi
vector
use
compani
prosavin
chanex
procastat
candid
gene
therapi
parkinson
diseas
cystic
fibrosi
prostat
cancer
respect
deltagen
deltagen
privat
fund
biotechnolog
compani
focus
use
knockout
mous
molecular
genet
unlock
vivo
function
novel
gene
order
develop
new
therapeut
target
deltagen
agreement
roch
merck
tularik
amgen
pfizer
provid
servic
devgen
devgen
found
headquart
ghent
belgium
achiev
ipo
june
privat
own
genomicsbas
biotechnolog
compani
focus
use
model
organ
c
elegan
target
valid
drug
discoveri
galapago
galapago
cambridg
uk
establish
function
genom
compani
galapago
two
technolog
base
adenovir
vector
system
highthroughput
miniatur
autom
platform
galapago
achiev
ipo
may
acquir
biofocu
saffron
walden
uk
octob
establish
broadbas
target
drug
discoveri
compani
jurilab
jurilab
kuopio
finland
privat
own
compani
found
research
institut
public
health
univers
kuopio
finland
jurilab
develop
proprietari
method
identifi
verifi
dna
variat
known
hierarch
phenotypetarget
sequenc
mean
find
new
function
import
mutat
human
speci
technolog
use
identifi
novel
variant
associ
prostat
cancer
type
diabet
potenti
use
predict
test
therapeut
target
lexicon
genet
lexicon
genet
woodland
tx
found
gene
target
embryon
stem
cell
technolog
ip
baylor
colleg
medicin
lexicon
use
proprietari
gene
knockout
technolog
identifi
suitabl
target
human
genom
investig
ligand
protein
develop
treatment
metabol
disord
cardiovascular
diseas
immunolog
disord
neurolog
disord
cancer
juli
lexicon
complet
merger
chemistri
servic
compani
coelacanth
sinc
becom
drug
discoveri
arm
origin
target
discoveri
compani
paradigm
therapeut
paradigm
therapeut
discoveri
compani
focus
novel
drug
target
identifi
human
genom
paradigm
start
spinout
compani
univers
cambridg
sinc
establish
platform
base
mous
transgen
technolog
defin
biolog
function
previous
uncharacter
human
druggabl
protein
paradigm
collabor
medivir
identifi
novel
proteas
drug
target
discov
smallmolecul
proteas
inhibitor
drug
paradigm
acquir
chemistri
arm
amedi
pharmaceut
pharmagen
pharmagen
royston
cambridg
found
april
first
uk
compani
focu
entir
use
human
tissu
drug
discoveri
focus
express
function
gene
gene
product
offer
target
valid
servic
targetevalu
provid
inform
express
gene
rang
diseas
nondiseas
tissu
larg
number
compani
computeraid
drug
design
compani
computeraid
drug
design
play
major
part
hitfind
activ
silico
screen
dock
ligand
protein
caviti
optim
predict
potenc
properti
molecul
computeraid
predict
often
suffici
guid
valu
make
compound
compani
base
martinsri
near
munich
germani
found
use
technolog
predict
rank
biolog
properti
martinsri
provid
servic
major
compani
like
sanofiaventi
smaller
compani
like
spain
accelri
accelri
san
diego
ca
longstand
supplier
softwar
servic
worldwid
pharmaceut
drug
discoveri
undergon
seri
name
chang
acquisit
product
formerli
market
molecular
simul
synopsi
pharmacopeia
oxford
molecular
name
cresset
biomolecular
discoveri
cresset
biomolecular
discoveri
letchworth
uk
recent
creat
sme
fieldbas
virtual
screen
technolog
use
exampl
partner
jame
black
foundat
london
biofocu
de
novo
pharmaceut
de
novo
pharmaceut
spinout
pharmacolog
depart
univers
cambridg
uk
proprietari
comput
softwar
structurebas
drug
design
creat
novel
patent
lead
molecul
candid
drug
develop
scientist
de
novo
recent
advanc
understand
hydrophob
group
drugprotein
dock
interact
inpharmatica
inpharmatica
london
uk
spun
univers
colleg
london
aim
identifi
novel
drug
target
integr
computermodel
techniqu
genom
data
well
provid
servic
drug
discoveri
player
signal
success
techniqu
worker
inpharmatica
report
identif
molecular
basi
biolog
role
nicastrin
potenti
new
protein
drug
target
alzheim
diseas
use
proprietari
databas
compani
found
portion
protein
signific
similar
known
proteas
suggest
region
confer
peptidebind
function
nicastrin
libraria
libraria
san
jose
ca
proprietari
softwar
captur
evalu
structureact
chemic
synthesi
relationship
autom
recognit
relev
pattern
permit
design
new
patent
small
molecul
compani
initi
focu
kinas
tripo
tripo
st
loui
mo
longstand
found
sme
supplier
computeraid
drug
design
servic
also
work
chemistri
drug
discoveri
use
uk
subsidiari
tripo
discoveri
research
recent
tripo
pioneer
idea
lead
hop
get
patent
seri
china
previous
establish
compani
elect
set
subsidiari
take
advantag
hightechnolog
cheaper
workforc
albani
molecular
singapor
appar
improv
abil
compani
enforc
ip
right
india
china
partli
respons
increas
shift
outsourc
drug
discoveri
activ
countri
one
consequ
shift
willing
us
servic
provid
set
satellit
oper
india
singapor
pharmacopeia
take
advantag
reduc
cost
base
competit
market
hightechnolog
biolog
screen
engin
long
sourc
expert
engin
compani
technolog
partnership
melbourn
uk
form
consortium
astrazeneca
develop
laserscreen
engin
cellular
screen
instrument
competit
anoth
smeinspir
devic
optic
highthroughput
screen
engin
develop
axon
instrument
acquir
juli
molecular
devic
union
citi
ca
develop
theme
sme
continu
develop
difficult
screen
technolog
particularli
ion
channel
screen
requir
personnel
biophys
disciplin
rare
typic
drug
discoveri
compani
includ
cene
cambridg
uk
axon
instrument
ca
latter
develop
two
product
ion
channel
screen
parallel
electrophysiolog
system
ion
channel
activ
eight
oocyt
time
record
automat
instrument
parallel
record
ion
channel
mammalian
cell
line
use
patchclamp
techniqu
sme
compani
perform
highthroughput
screen
servic
includ
biofocu
discoveri
also
evotec
technolog
affili
evotecoai
germani
evotec
pioneer
ultrahighthroughput
screen
develop
support
consortium
includ
glaxosmithklin
novarti
evotec
perform
contract
highthroughput
screen
target
novarti
hit
lead
optim
compani
us
biofocu
dpi
saffron
walden
uk
argenta
discoveri
harlow
uk
evotecoai
hamburg
germani
oxford
uk
nikem
milan
itali
big
pharma
partner
includ
glaxosmithklin
nikem
argenta
j
j
biofocu
dpi
novarti
argenta
discoveri
gener
big
pharma
outsourc
activ
intern
capac
constraint
rather
perceiv
lack
technolog
critic
factor
gener
recogn
medicin
chemistri
optim
stage
experi
valuabl
end
compani
like
biofocu
discoveri
concentr
project
substanti
inhous
expertis
built
project
involv
kinas
target
ion
channel
target
target
case
nich
technolog
area
acquir
sme
perform
contract
drug
discoveri
big
pharma
larg
abandon
natur
product
sourc
hit
drug
late
nonetheless
natur
product
sme
exist
one
case
biofrontera
compani
recent
acquir
dpi
march
may
natur
product
research
kept
aliv
futur
specialist
sme
compani
rather
big
pharma
research
center
compani
offer
expert
pharmacolog
valid
compet
establish
major
player
includ
renasci
nottingham
uk
metabol
obes
cn
diseas
area
oncodesign
dijon
franc
oncolog
argenta
discoveri
respiratori
diseas
huge
number
compani
offer
servic
interest
drug
discoveri
fact
disciplin
purchas
import
adjunct
servic
provid
list
includ
protein
xray
crystallographi
aid
drug
discoveri
crystallin
drugabl
target
exampl
structur
biolog
compani
astex
technolog
cambridg
uk
structur
biolog
compani
form
juli
recent
move
proprietari
oncolog
drug
discoveri
syrrx
san
diego
ca
intern
ip
oncolog
target
includ
histon
deacetylas
compani
purchas
outright
takeda
japan
crystal
genom
korea
structur
genomix
san
diego
ca
plexxicon
berkeley
ca
plexxicon
like
mani
servic
compani
also
move
proprietari
drug
discoveri
plexxicon
ckit
inhibitor
develop
project
collabor
phenomix
treatment
cancer
inflamm
custom
radiosynthesi
assist
compound
valid
offer
sme
like
selcia
ongar
uk
becam
independ
former
parent
scynexi
valu
smallor
mediums
enterpris
drug
discoveri
last
year
analysi
effect
sme
drug
discoveri
cours
taken
patient
point
view
difficult
give
overal
assess
recent
launch
drug
form
input
sme
organ
howev
possibl
perform
analysi
drug
reach
market
past
year
whose
ip
origin
sme
perform
analyz
chapter
entitl
market
market
year
edit
annual
report
medicin
chemistri
survey
origin
new
drug
year
show
tabl
figur
proport
new
drug
origin
laboratori
bigtradit
pharma
stay
steadi
around
depend
individu
compani
proport
new
drug
origin
biotech
sector
compani
sme
sme
patent
file
grown
substanti
academ
sourc
drug
remain
steadi
sector
contract
small
pharma
organ
subsidiari
larger
conglomer
pharmaceut
manufactur
gener
compani
mani
japanes
compani
sourc
new
drug
earli
part
year
note
year
survey
major
new
drug
invent
sme
brought
market
tradit
pharma
compani
licens
taken
thirdparti
product
origin
sme
compani
acquir
although
contribut
sme
drug
discoveri
clear
similar
analysi
shown
reveal
product
invent
sme
actual
market
particularli
earli
year
compani
market
becom
viabl
sme
becom
fipco
right
amgen
genentech
serono
etc
sme
rout
market
preciou
candid
drug
still
lie
tradit
pharma
compani
licens
product
acquir
compani
time
write
largest
pharmaceut
compani
world
pfizer
analysi
r
pipelin
term
compound
origin
tabl
allow
crude
estim
product
pfizer
might
make
avail
patient
futur
might
invent
smebiotech
compani
first
edit
comprehens
medicin
chemistri
written
major
drug
discoveri
perform
establish
larg
small
pharma
compani
market
size
compani
put
clinic
trial
drug
either
discov
inhous
team
chemist
crosslicens
larg
compani
littl
crosslicens
occur
clinic
develop
stage
compani
usual
tradit
locat
close
industri
root
often
rel
far
apart
geograph
situat
vastli
differ
impact
merger
sinc
creat
mammoth
compani
smithklin
beecham
wellcom
glaxo
part
glaxosmithklin
warner
lambert
pharmacia
pfizer
known
pfizer
howev
combin
major
pharmaceut
compani
spawn
whole
host
spinout
compani
mani
field
drug
discoveri
addit
mani
univers
recogn
worth
ip
gener
creat
spinout
sme
compani
maxim
drug
discoveri
multidisciplinari
task
sme
ever
becom
profici
disciplin
major
sme
compani
becom
intens
interdepend
enforc
share
object
ideal
form
biotech
commun
california
massachusett
medicon
valley
amongst
other
emul
territori
like
singapor
local
commun
provid
forum
intellectu
discuss
lead
innov
recogn
big
pharma
case
move
r
site
geograph
cluster
mani
thousand
biotechsm
creat
past
year
two
reach
exalt
big
pharma
statu
anoth
pois
join
exalt
throng
salutari
except
celltech
uk
part
ucb
serono
switzerland
acquisit
target
earli
us
term
drug
discoveri
one
year
depend
compani
market
product
origin
biotech
compani
vast
develop
sum
requir
develop
market
potenti
medicin
usual
larg
biotech
resourc
big
pharma
appear
maintain
tradit
preponder
invent
drug
nonetheless
like
biotech
signific
ultim
major
sourc
new
drug
big
pharma
ultim
patient
popul
concept
big
pharma
may
entir
abandon
research
group
sourc
compound
entir
smebiotech
organ
howev
still
look
unjustifi
basi
analysi
pfizer
pipelin
remain
way
happen
potenti
medicin
reach
clinic
trial
statu
cardiovascular
respiratori
inflammatori
disord
chri
receiv
msc
phd
degre
organ
chemistri
turner
prize
univers
sheffield
respect
award
ba
degre
natur
scienc
emeleu
prize
univers
cambridg
respect
member
american
chemic
societi
royal
societi
chemistri
sci
societi
drug
research
uk
contribut
organ
numer
scientif
meet
elsevi
ltd
right
reserv
comprehens
medicin
chemistri
ii
part
public
may
reproduc
store
retriev
system
transmit
form
mean
electron
electrostat
magnet
tape
mechan
photocopi
record
otherwis
without
permiss
write
publish
isbn
set
isbn
volum
pp
role
smallor
mediums
enterpris
drug
discoveri
